Research Article

Clinical and Translational Oncology

, Volume 15, Issue 1, pp 26-32

First online:

Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM

  • Alka MadaanAffiliated withDabur Research Foundations
  • , Pratibha SinghAffiliated withDabur Research Foundations
  • , Anshumali AwasthiAffiliated withDabur Research Foundations
  • , Ritu VermaAffiliated withDabur Research Foundations
  • , Anu T. SinghAffiliated withDabur Research Foundations
  • , Manu JaggiAffiliated withDabur Research Foundations
  • , Shiva Kant MishraAffiliated withMedical Affairs and Clinical Research, Fresenius Kabi India Private Limited
  • , Sadanand KulkarniAffiliated withMedical Affairs and Clinical Research, Fresenius Kabi India Private Limited
  • , Hrishikesh KulkarniAffiliated withFresenius Kabi Asia Pacific Limited Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



An increasing research interest has been directed toward nanoparticle-based drug delivery systems for their advantages. The appropriate amalgamation of pH sensitivity and tumor targeting is a promising strategy to fabricate drug delivery systems with high efficiency, high selectivity and low toxicity.

Materials and Methods

A novel pH sensitive Cremophor-free paclitaxel formulation, NanoxelTM, was developed in which the drug is delivered as nanomicelles using a polymeric carrier that specifically targets tumors. The efficiency and mechanism of intracellular paclitaxel delivery by NanoxelTM was compared with two other commercially available paclitaxel formulations: AbraxaneTM and IntaxelTM, using different cell lines representing target cancers [breast, ovary and non-small cell lung carcinoma (NSCLC)] by transmission electron microscopy and quantitative intracellular paclitaxel measurements by high performance liquid chromatography.


The data obtained from the present study revealed that the uptake of nanoparticle-based formulations NanoxelTM and AbraxaneTM is mediated by the process of endocytosis and the uptake of paclitaxel was remarkably superior to IntaxelTM in all cell lines tested. Moreover, the intracellular uptake of paclitaxel in NanoxelTM- and AbraxaneTM-treated groups was comparable. Hence, the nanoparticle-based formulations of paclitaxel (NanoxelTM and AbraxaneTM) are endowed with higher efficiency to deliver the drug to target cells as compared to the conventional Cremophor-based formulation.


NanoxelTM appears to be of great promise in tumor targeting and may provide an advantage for paclitaxel delivery into cancer cells.


Paclitaxel Delivery system Tumor Naoxel Nanoparticle Intaxel